| Administration of Subcutaneous Medications in Palliative Care using a NIPRO Surefuser™
|
SESLHDPR/666 |
|
| Aerosol-generating interventions (AGI) for respiratory or cardiac conditions during the COVID-19 pandemic period
|
SESLHDBR/094 |
|
| Framework for Managing Nursing and Midwifery Staff with Identified Practice Issues
|
SESLHDPD/270 |
|
| Injury Management - Non-Work Related Injury or Illness Management
|
SESLHDPR/564 |
|
| Management of the Deteriorating NEONATAL Inpatient
|
SESLHDPR/340 |
|
| Managing Notifiable Incidents and Regulator Interactions
|
SESLHDPR/269 |
|
| Naltrexone for treatment of long-acting opioid poisoning
|
SESLHDPR/651 |
|
| Name Badges
|
SESLHDPR/233 |
|
| Neonatal Services Demand Management and Escalation Policy
|
SESLHDPD/304 |
|
| Network Security Policy
|
SESLHDPD/313 |
|
| New or altered interventional procedures, technologies including devices, implants, point of care (POC) diagnostic machines or treatments – safe introduction into clinical practice
|
SESLHDPD/286 |
|
| Noise Risk Management
|
SESLHDPR/394 |
|
| Notification of Death of Non-inpatients from an External Source
|
SESLHDPR/216 |
|
| Nursing and Midwifery Registration
|
SESLHDPD/030 |
|
| Nursing Observation for Total and Completion Thyroidectomy
|
SESLHDGL/046 |
|
| Observation of the neonate following instrumental delivery
|
SESLHDPR/414 |
|
| Smoking Cessation: Nurse/Midwife Initiated Nicotine Replacement Therapy (NRT)
|
SESLHDPR/494 |
|
| Take-home naloxone under the Opioid Overdose Response and Take Home Naloxone (ORTHN) intervention (Nyxoid® or Prenoxad®)
|
SESLHDPR/658 |
|
